Healthcare imaging solution company Median Technologies (ALMDT:PA) reported revenues of EUR20.5m as of 31 December 2021.
This marks an improvement of 52% when compared to revenues in 2020.
The company generated EUR5.1m in revenue in the Q4 2021, a rise of 24.4% over the revenue of EUR4.1m in the Q4 2020.
In addition, the company's order backlog was EUR58m as of 31 December 2021, up by EUR6.3m from 31 December 2020 and EUR3,8m from 30 September 2021, respectively. The increase confirms the growth momentum recovery that began in the third quarter after several quarters impacted by the health crisis.
As of 31 December 2021, the company's cash and cash equivalents were EUR39m, a growth over EUR16m as of 31 December 2020.
For 2021, the company was selected as preferred vendor for one of the world's Top 3 pharmaceutical companies to implement this client's imaging strategy in clinical trials on key oncology indications. The company was inspected by the FDA at its location of Sophia Antipolis, France and participated in 4 NMPA inspections (Chinese authority regulating drugs and medical devices) on behalf of a several clients.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial